Personalized Feedback for Smokers With Elevated Anxiety Sensitivity

Sponsor
University of Houston (Other)
Overall Status
Completed
CT.gov ID
NCT03382093
Collaborator
National Institute on Drug Abuse (NIDA) (NIH)
95
1
2
21.3
4.5

Study Details

Study Description

Brief Summary

This project will develop and refine a computer-delivered integrated Personalized Feedback Intervention (PFI) that directly addresses smoking and anxiety sensitivity (AS). The PFI will focus on feedback about smoking behavior, AS, and adaptive coping strategies.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Personalized Feedback Intervention
  • Behavioral: Smoking Information Control
N/A

Detailed Description

The primary goal of the research study is to investigate the efficacy of a brief, personalized computer-delivered transdiagnostic intervention (PFI) that addresses smoking and anxiety sensitivity (AS) to reduce smoking, increase quit attempts, reduce perceived barriers to cessation, reduce AS and negative affective symptoms, and increase adaptive coping skills compared to a smoking information only control. To address this aim, we will implement a randomized controlled trial that will employ a longitudinal experimental design and involve three stages: (a) phone-screener (pre-screener); (b) baseline appointment consisting of a pre-intervention assessment (eligibility), random assignment to a one-session computer-delivered intervention (PFI versus smoking information control with no personalized feedback), and a post-intervention assessment; (c) 1-month follow-up. Assessments will include a multi-method approach, including biological, behavioral, and self-report methods.

Study Design

Study Type:
Interventional
Actual Enrollment :
95 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
If participant meets eligibility criteria, the participant will be randomly assigned to complete a computer-delivered intervention: either the (a) Personalized Feedback Intervention or (b) smoking information control.If participant meets eligibility criteria, the participant will be randomly assigned to complete a computer-delivered intervention: either the (a) Personalized Feedback Intervention or (b) smoking information control.
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Personalized Feedback for Smokers With Elevated Anxiety Sensitivity
Actual Study Start Date :
Aug 23, 2017
Actual Primary Completion Date :
Jun 1, 2019
Actual Study Completion Date :
Jun 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Personalized Feedback Intervention

A brief, personalized computer-delivered transdiagnostic intervention (PFI) that addresses smoking and anxiety sensitivity (AS) to reduce smoking, increase quit attempts, reduce perceived barriers to cessation, reduce AS and negative affective symptoms, and increase adaptive coping skills.

Behavioral: Personalized Feedback Intervention
Personalized Feedback Intervention for smoking and anxiety.
Other Names:
  • PFI
  • Active Comparator: Smoking Information Control

    Standard, computer-delivered smoking cessation treatment/information.

    Behavioral: Smoking Information Control
    Smoking Information with no personalized feedback.
    Other Names:
  • Control
  • Clearing the Air Pamphlet
  • Outcome Measures

    Primary Outcome Measures

    1. Evaluate PFI [Assessed at 1-month follow-up after the one-session intervention]

      Evaluate the protocol for a brief personalized, computer-delivered intervention. Assessed by program evaluation survey.

    Secondary Outcome Measures

    1. Smoking Motivational Processes [Assessed at 1-month follow-up after the one-session intervention]

      Smokers in intervention, relative to a smoking information control, will report increased motivation and confidence for quitting smoking. Assessed using Smoking Rulers for Change measure.

    2. Smoking Behavior [Assessed at 1-month follow-up after the one-session intervention]

      Smokers in intervention, relative to a smoking information control, will report reduced smoking rates. Assessed using Carbon Monoxide [CO] analysis.

    3. Affective Processes [Assessed at 1-month follow-up after the one-session intervention]

      Smokers in intervention, relative to a smoking information control, will report greater reductions in anxiety sensitivity. Assessed using Anxiety Sensitivity Index measure.

    4. Mechanisms [Assessed at 1-month follow-up after the one-session intervention]

      Smokers in the intervention, relative to the smoking information control, will report decreased positive consequences for continued smoking. Assessed using Smoking Consequence Questionnaire.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Elevated anxiety sensitivity defined as an ASI-III score of at least 17

    • Daily smoking for at least one year (minimum of 5 cigarettes per day and biochemically confirmed via Carbon Monoxide [CO] analysis at least 4 ppm)

    • Not presently engaged in a quit attempt

    • Not currently engaged in mental health treatment

    • Capable of providing informed consent

    • Willing to attend all study visits and comply with the protocol

    Exclusion Criteria:
    • Adults unable to consent

    • Individuals who are not yet adults (infants, children, teenagers)

    • Pregnant women

    • Prisoners

    • Students for whom you have direct access to/influence on grades

    • Use of other tobacco products

    • Currently suicidal or high suicide risk

    • Currently psychotic or high psychotic risk

    • Insufficient command of English to participate in assessment or treatment

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Anxiety and Health Research Laboratory and Substance Use Treatment Clinic, University of Houston Houston Texas United States 77204

    Sponsors and Collaborators

    • University of Houston
    • National Institute on Drug Abuse (NIDA)

    Investigators

    • Principal Investigator: Lorra L. Garey, MA, University of Houston
    • Principal Investigator: Michael J. Zvolensky, PHD, University of Houston

    Study Documents (Full-Text)

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Lorra Garey, Clinical Psychology Doctoral Student, University of Houston
    ClinicalTrials.gov Identifier:
    NCT03382093
    Other Study ID Numbers:
    • CR00000267
    • 5F31DA043390-02
    First Posted:
    Dec 22, 2017
    Last Update Posted:
    Jun 19, 2019
    Last Verified:
    Jun 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Lorra Garey, Clinical Psychology Doctoral Student, University of Houston
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 19, 2019